董事
Brian Guan-Chyun Liu, M.D., is a director of CG Oncology, Inc. (CGON) and a healthcare-focused venture capitalist.[[1]](https://www.insidertrades.com/cg-oncology-inc-common-stock-stock/brian-guan-chyun-liu/)[[8]](https://www.stocktitan.net/sec-filings/CGON/form-4-cg-oncology-inc-insider-trading-activity-873ba062c55e.html) He has served on CG Oncology’s board of directors since September 2022 and is an active corporate insider, including recent open‑market purchases of CG Oncology common stock through Seven Fleet Partners LP, an investment vehicle with which he is affiliated.[[1]](https://www.insidertrades.com/cg-oncology-inc-common-stock-stock/brian-guan-chyun-liu/)[[3]](https://www.moomoo.com/hans/news/post/72212688/cg-oncology-insider-bought-shares-worth-24814454-according-to-a)[[8]](https://www.stocktitan.net/sec-filings/CGON/form-4-cg-oncology-inc-insider-trading-activity-873ba062c55e.html) In a June 25, 2026 Form 4 filing, Seven Fleet Partners LP, whose investment manager is Seven Fleet Advisors, LLC led by Liu as managing member, acquired 371,085 CG Oncology shares at $66.87 per share, bringing its indirectly reported holdings associated with Liu to 1,886,236 shares.[[3]](https://www.moomoo.com/hans/news/post/72212688/cg-oncology-insider-bought-shares-worth-24814454-according-to-a)[[8]](https://www.stocktitan.net/sec-filings/CGON/form-4-cg-oncology-inc-insider-trading-activity-873ba062c55e.html)
Professionally, Liu is a Managing Director at Longitude Capital, a healthcare venture capital firm he joined in 2018, following earlier experience as an Engagement Manager in the pharmaceuticals practice at McKinsey & Company from 2016 to 2018.[[1]](https://www.insidertrades.com/cg-oncology-inc-common-stock-stock/brian-guan-chyun-liu/) He has broad board and board‑observer experience in biotechnology and pharmaceuticals, including director service at Lassen Therapeutics and board‑observer roles at Quanta Therapeutics, Rivus Pharmaceuticals, Zenas BioPharma, and prior observer roles at Endeavor Biomedicines, Inflazome, Dascena Lab, Talaris Therapeutics, and Vera Therapeutics.[[1]](https://www.insidertrades.com/cg-oncology-inc-common-stock-stock/brian-guan-chyun-liu/) Liu holds an M.D. from the Stanford School of Medicine and a B.S. in Biomedical Engineering from Johns Hopkins University, and CG Oncology cites his investment experience in the pharmaceutical industry and prior board service as key reasons for his appointment as director.[[1]](https://www.insidertrades.com/cg-oncology-inc-common-stock-stock/brian-guan-chyun-liu/)
查看完整内部人档案 →